Fate Therapeutics, Inc. (FATE) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 1.3M | 1.37M | 1.74M | 1.91M | 1.63M | 1.86M | 3.07M | 6.77M | 1.93M | 1.68M | 1.94M | 933K |
| Revenue Growth % | -20.26% | -26.4% | -43.36% | -71.84% | -15.38% | 10.98% | 58.13% | 625.83% | -96.74% | -96.22% | -87.02% | -94.97% |
| Cost of Goods Sold | 2.92M | 0 | 0 | 0 | 0 | 0 | 0 | 4.72M | 4.82M | 4.88M | 4.74M | 40.88M |
| COGS % of Revenue | 224.63% | - | - | - | - | - | - | 69.71% | 250.44% | 291.47% | 243.83% | 4381.14% |
| Gross Profit | -1.62M | 1.37M | 1.74M | 1.91M | 1.63M | 1.86M | 3.07M | 2.05M | -2.9M | -3.21M | -2.8M | -39.94M |
| Gross Margin % | -124.63% | 100% | 100% | 100% | 100% | 100% | 100% | 30.29% | -150.44% | -191.47% | -143.83% | -4281.14% |
| Gross Profit Growth % | -199.39% | -26.4% | -43.36% | -7.02% | 156.25% | 157.96% | 209.94% | 105.13% | 56.44% | 92.51% | 95.69% | 36.35% |
| Operating Expenses | 31.38M | 36.09M | 36.48M | 38.88M | 42.91M | 63.61M | 55.45M | 47.13M | 48.17M | 44.87M | 48.48M | 22.62M |
| OpEx % of Revenue | 2415.78% | 2636.23% | 2095.12% | 2038.54% | 2634.07% | 3419.78% | 1803.87% | 696.01% | 2502.44% | 2676.97% | 2493.98% | 2424.65% |
| Selling, General & Admin | 9.6M | 10.66M | 10.64M | 11.45M | 13.77M | 15.26M | 20.8M | 17.25M | 20.86M | 17.93M | 18.95M | 22.62M |
| SG&A % of Revenue | 738.72% | 779.04% | 611.03% | 600.16% | 845.49% | 820.54% | 676.68% | 254.74% | 1083.38% | 1070.11% | 974.69% | 2424.65% |
| Research & Development | 21.79M | 25.43M | 25.84M | 27.43M | 29.14M | 33.61M | 34.65M | 34.6M | 32.14M | 31.82M | 34.27M | 40.88M |
| R&D % of Revenue | 1677.06% | 1857.2% | 1484.09% | 1438.38% | 1788.58% | 1806.94% | 1127.2% | 510.99% | 1669.51% | 1898.33% | 1763.12% | 4381.14% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 1000K | 0 | -1000K | -1000K | -1000K | -1000K | -1000K |
| Operating Income | -33M | -34.72M | -34.73M | -36.97M | -41.28M | -61.75M | -52.38M | -45.08M | -51.07M | -48.08M | -51.28M | -62.56M |
| Operating Margin % | -2540.42% | -2536.23% | -1995.12% | -1938.54% | -2534.07% | -3319.78% | -1703.87% | -665.73% | -2652.88% | -2868.44% | -2637.81% | -6705.79% |
| Operating Income Growth % | 20.06% | 43.77% | 33.68% | 18% | 19.17% | -28.44% | -2.14% | 27.94% | -78.61% | 25.37% | 40.64% | 24.72% |
| EBITDA | -30.08M | -31.66M | -31.51M | -33.69M | -37.95M | -56.94M | -47.77M | -40.36M | -46.25M | -43.19M | -46.54M | -58.1M |
| EBITDA Margin % | -2315.78% | -2312.49% | -1809.76% | -1766.65% | -2329.47% | -3061.02% | -1554% | -596.01% | -2402.44% | -2576.97% | -2393.98% | -6227.12% |
| EBITDA Growth % | 20.73% | 44.4% | 34.04% | 16.53% | 17.95% | -31.82% | -2.65% | 30.53% | -89.53% | 27.51% | 44.06% | 27.51% |
| D&A (Non-Cash Add-back) | 2.92M | 3.06M | 3.23M | 3.28M | 3.33M | 4.81M | 4.61M | 4.72M | 4.82M | 4.88M | 4.74M | 4.47M |
| EBIT | -33M | -34.72M | -32.25M | -34.07M | -41.28M | -47.01M | -52.38M | -45.08M | -51.07M | -48.08M | -51.28M | -62.56M |
| Net Interest Income | 1.87M | 2.22M | 2.58M | 2.92M | 3.34M | 3.87M | 4.44M | 4.83M | 4.15M | 4.41M | 4.7M | 4.38M |
| Interest Income | 1.87M | 2.22M | 2.58M | 2.92M | 3.34M | 3.87M | 4.44M | 4.83M | 4.15M | 4.41M | 4.7M | 4.38M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.79M | 2.35M | 2.48M | 2.9M | 3.66M | 9.6M | 4.7M | 6.66M | 3.06M | 3.95M | 6.11M | 9.81M |
| Pretax Income | -31.21M | -32.37M | -32.25M | -34.07M | -37.62M | -52.15M | -47.68M | -38.43M | -48M | -44.12M | -45.17M | -52.76M |
| Pretax Margin % | -2402.85% | -2364.79% | -1852.38% | -1786.58% | -2309.45% | -2803.92% | -1551.01% | -567.44% | -2493.71% | -2632.58% | -2323.56% | -5654.34% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -31.21M | -32.37M | -32.25M | -34.07M | -37.62M | -52.15M | -47.68M | -38.43M | -48M | -44.12M | -45.17M | -52.76M |
| Net Margin % | -2402.85% | -2364.79% | -1852.38% | -1786.58% | -2309.45% | -2803.92% | -1551.01% | -567.44% | -2493.71% | -2632.58% | -2323.56% | -5654.34% |
| Net Income Growth % | 17.03% | 37.92% | 32.36% | 11.34% | 21.63% | -18.2% | -5.55% | 27.16% | -154.25% | 21.72% | 45.95% | 30.68% |
| Net Income (Continuing) | -31.21M | -32.37M | -32.25M | -34.07M | -37.62M | -52.15M | -47.68M | -38.43M | -48M | -44.12M | -45.17M | -52.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |
| EPS Growth % | 18.75% | 38.64% | 32.5% | 12.12% | 31.91% | 2.22% | 13.04% | 38.89% | -402.67% | 10% | 44.58% | 31.65% |
| EPS (Basic) | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |
| Diluted Shares Outstanding | 120.03M | 118.79M | 119M | 118.53M | 118.38M | 117.79M | 117.77M | 117.47M | 101.1M | 98.61M | 98.57M | 98.4M |
| Basic Shares Outstanding | 120.03M | 118.79M | 119M | 118.53M | 118.38M | 117.79M | 117.77M | 117.47M | 101.1M | 98.61M | 98.57M | 98.4M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |